Filing Flows

Filing Flows › Companies › Verrica Pharmaceuticals › Cash flow

Verrica Pharmaceuticals cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$9.3M in Q2 2026 · −$13.3M over twelve months

Operating cash flow−$9.3M
Free cash flow−$9.3M

Analysis

In Q2 2026, Verrica Pharmaceuticals generated −$9.3M of operating cash flow. That is $766K more than in Q2 2025 (−$10.0M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$13.3M; the largest uses were operating cash flow ($13.3M), net borrowing (+) / repaid (−) ($437K); besides operations, cash came from other financing ($9.8M); the cash balance fell by $3.9M.

Operating cash flow was −$9.3M against net income of −$13.2M. The largest differences: receivables −$3.2M, stock-based pay +$1.2M, inventory −$738K.

Free cash flow

Verrica Pharmaceuticals: free cash flow by quarterVerrica Pharmaceuticals: free cash flow by quarter−$8.6MQ3 2024−$16.1MQ4 2024−$12.7MQ1 2025−$10.0MQ2 2025$9.7MQ3 2025−$4.6MQ4 2025−$9.2MQ1 2026−$9.3MQ2 2026
Operating cash flow less capital spending.
Verrica Pharmaceuticals: operating cash flow against capital spendingVerrica Pharmaceuticals: operating cash flow against capital spendingOperating cash flowCapital spending−$8.6M$16KQ3 2024−$16.1M$0Q4 2024−$12.7M$0Q1 2025−$10.0M$0Q2 2025$9.7M$0Q3 2025−$4.6M$0Q4 2025−$9.2M$0Q1 2026−$9.3M$0Q2 2026
Latest (Q2 2026): Operating cash flow −$9.3M, Capital spending $0.

Capital allocation, year by year

Verrica Pharmaceuticals: where the cash came from (up) and went (down), by fiscal yearVerrica Pharmaceuticals: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingFY2021: Operating cash flow −$27.6MFY2021: Net borrowing $5.0MFY2021: Shares issued $28.7MFY2021: Capital spending −$883K$33.6MFY2021FY2022: Operating cash flow −$18.6MFY2022: Net borrowing −$4KFY2022: Shares issued $26.9MFY2022: Capital spending −$302K$26.9MFY2022FY2023: Operating cash flow −$38.6MFY2023: Net borrowing $44.1MFY2023: Shares issued $7KFY2023: Capital spending −$362K$44.1MFY2023FY2024: Operating cash flow −$60.9MFY2024: Net borrowing −$924KFY2024: Shares issued $155KFY2024: Asset sales $8KFY2024: Capital spending −$27K$163KFY2024FY2025: Operating cash flow −$17.6MFY2025: Net borrowing −$383KFY2025
Over these 5 years operating cash flow totalled −$163M; the largest uses were operating cash flow ($163M) and capital spending ($1.6M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$11.2M
Debtnone
Net cash$11.2M
Due within a year$15.7M
Cash runway10 months

Verrica Pharmaceuticals is burning cash: its operations consume cash, a free cash flow of −$13.3M a year at the current rate against $11.2M of cash and investments: a runway of about 10 months; $15.7M of debt also comes due within a year, which would need refinancing or new money before any new financing.

Verrica Pharmaceuticals: debt maturities by year (FY2024)Verrica Pharmaceuticals: debt maturities by year (FY2024)$15.7MYear 1$15.3MYear 2$15.0MYear 3$8.8MYear 4
Principal due in each year as disclosed in the annual report, against $11.2M of cash and investments now.

Where the cash came from and went

Verrica Pharmaceuticals: sources (+) and uses (−) of cash, Q2 2026Verrica Pharmaceuticals: sources (+) and uses (−) of cash, Q2 2026Cash drawn (+) / kept (−)$9.4MOperating cash flow−$9.3MNet borrowing (+) / repaid (−)−$126K
Verrica Pharmaceuticals: sources (+) and uses (−) of cash, TTM to Q2 2026Verrica Pharmaceuticals: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow−$13.3MOther financing$9.8MCash drawn (+) / kept (−)$3.9MNet borrowing (+) / repaid (−)−$437K

From profit to cash

Verrica Pharmaceuticals: net income to operating cash flow, Q2 2026Verrica Pharmaceuticals: net income to operating cash flow, Q2 2026Net income−$13.2MDepreciation & amortization$15KStock-based pay$1.2MReceivables−$3.2MInventory−$738KPayables−$590KDeferred revenue$304KPrepaid and other assets−$251KOperating cash flow−$9.3M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q1 202574316215176
Q4 20246290165132

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$9.3M—−$126K—$9.4M−$9.3M
Q1 2026−$9.2M—−$111K—$9.3M−$9.2M
Q4 2025−$4.6M—−$106K—−$9.1M−$4.6M
Q3 2025$9.7M—−$94K—−$5.7M$9.7M
Q2 2025−$10.0M—−$85K—$14.2M−$10.0M
Q1 2025−$12.7M—−$98K—$16.7M−$12.7M
Q4 2024−$16.1M—−$374K$1K−$23.4M−$16.1M
Q3 2024−$8.6M−$16K−$217K—$9.0M−$8.6M

Verrica Pharmaceuticals: income statement and cash flow

Verrica Pharmaceuticals, Q2 2026: revenue $5.9M (-54% year over year), operating margin -223.4%. The chart follows the revenue to costs, profit and cash.

Verrica Pharmaceuticals: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.